Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: An analysis alongside a multicenter, randomized phase III clinical trial

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 278-285

  Maniadakis, Nikos ^a   Dafni, U ^b   Fragoulakis, V ^c   Grimani, I ^d   Galani, E ^e   Fragkoulidi, A ^f   Fountzilas, G ^f  

^a UNIVERSITY OF PIRAEUS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Social Insurance Institute   (Greece)

^d Hellenic Cooperative Oncology Group   (Greece)

^e HENRY DUNANT HOSPITAL   (Greece)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Breast cancer; Docetaxel; Economic evaluation; Gemcitabine; Paclitaxel

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; DOCETAXEL; ERYTHROPOIETIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; FEMALE; GREECE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FEMALE; GREECE; HUMANS; NEOPLASM METASTASIS; PACLITAXEL; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL RATE; TAXOIDS;

EID: 60549106227     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn634     Document Type: Article

References (22)

1. Global Burden of Disease Estimates, World Health Organization. Geneva, Switzerland: World Health Organization 2007 http://www.who.int (August 2008, date last accessed).
2. Cancer Trends Progress Report - 2005 Update. Bethesda, MD: National Cancer Institute, NIH, DHHS 2005 http://progressreport.cancer.gov (August 2008, date last accessed).
3. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In Harris JR, Lippman ME, Morrow M et al. Diseases of the Breast. Philadelphia, PA: PA Lippincot & Wilkins 2000; 749-798.
4. Fountzilas G, Dafni U, Dimopoulos MA et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2008 May 16. [online access].
5. Ramsey S, Willke R, Briggs A et al. Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report. Value Health 2005; 8: 521-533.
6. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, New York: Oxford University Press 1997.
7. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford University Press 1996.
8. Szende Agota, Oppe Mark, Devlin Nancy. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Series: EuroQol Group Monographs. Vol. 2. The Netherlands: Springer 2007.
9. Kontodimopoulos N, Pappa E, Niakas D et al. Validity of the EuroQoL (EQ-5D) instrument in a Greek General Population. Value Health 2008. May 16. [Epub ahead of print].
10. Yfantopoulos J. The Greek version of the EQ-5D instrument. Arch Hell Med 2001; 18: 180-191.
11. Greiner W, Weijnen T, Nieuwenhuizen M et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003; 4: 222-231.
12. Fountzilas G, Kalofonos HP, Dafni U et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004; 15: 1517-1526.
13. Lees M, Aristides M, Maniadakis N et al. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20: 325-337.
14. Aristides M, Lees M, Botwood N et al. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. Eur J Health Econ 2003; 4: 216-221.
15. Schiller J, Tilden D, Aristides M et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 2004; 43: 101-112.
16. Fountzilas G, Papakostas P, Dafni U et al. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2006; 17: 1560-1567.
17. Maniadakis N, Pallis A, Fragoulakis V et al. Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. Curr Med Res Opin 2007; 23: 2251-2257.
18. Maniadakis N, Fragoulakis V, Pallis A et al. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. Lung Cancer 2007; 58: 275-281.
19. Devlin N, Parkin D. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452.
20. Tengs TO. Cost-Effectiveness versus cost-utility analysis of interventions for cancer: Does adjusting for health-related quality of life really matter? Value Health 2004; 7: 70-78.
21. Eichler HG, Kong SX, Gerth WC et al. Use of cost-effectiveness analysis in healthcare resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-528.
22. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.